Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...
When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...
The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...
Hosted on MSN
What To Know About Metastatic Prostate Cancer
Metastatic prostate cancer is also referred to as stage 4 or advanced prostate cancer. It's cancer that began in the prostate, a gland located under the bladder of people assigned male at birth, and ...
Increased urinary urgency Frequent nighttime awakenings to urinate A slow or weak urinary flow Blood in the urine or semen As prostate cancer progresses and spreads to other areas of the body, it may ...
The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...
Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...
Men with metastatic noncastrate prostrate cancer (NCPC) experience a survival benefit with the addition of docetaxel (Taxotere, Pfizer) chemotherapy or abiraterone acetate (Zytiga, Janssen) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback